Next Article in Journal
Trichophyton indotineae, an Emerging Drug-Resistant Dermatophyte: A Review of the Treatment Options
Next Article in Special Issue
Infections with Klebsiella pneumoniae in Children Undergoing Anticancer Therapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study
Previous Article in Journal
Impact of Supine versus Prone Positioning on Segmental Lumbar Lordosis in Patients Undergoing ALIF Followed by PSF: A Comparative Study
Previous Article in Special Issue
Hospitalizations for Acute Otitis and Sinusitis in Patients Living with HIV: A Retrospective Analysis of a Tertiary Center in Romania
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Diagnostic Accuracy of Procalcitonin and Its Combination with Other Biomarkers for Candidemia in Critically Ill Patients

by
Stelios Kokkoris
,
Epameinondas Angelopoulos
,
Aikaterini Gkoufa
,
Foteini Christodouli
,
Theodora Ntaidou
,
Evangelia Theodorou
,
Georgia Dimopoulou
,
Ioannis Vasileiadis
,
Panagiotis Kremmydas
and
Christina Routsi
*
First Department of Critical Care Medicine and Pulmonary Services, Medical School, National and Kapodistrian University of Athens, Evangelismos Hospital, 45-47 Ipsilantou Street, 10676 Athens, Greece
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(12), 3557; https://doi.org/10.3390/jcm13123557
Submission received: 23 April 2024 / Revised: 11 June 2024 / Accepted: 12 June 2024 / Published: 18 June 2024
(This article belongs to the Special Issue Clinical Aspects of Infectious Diseases)

Abstract

:
Background: The aim of this study was to investigate the usefulness of serum procalcitonin (PCT), C-reactive protein (CRP), neutrophil to lymphocyte count ratio (NLR), and their combination, in distinguishing candidemia from bacteremia in intensive care unit (ICU) patients. Methods: This is a retrospective study in ICU patients with documented bloodstream infections (BSIs) and with both serum PCT and CRP measurements on the day of the positive blood sample. Illness severity was assessed by sequential organ failure assessment (SOFA) score on both admission and BSI day. Demographic, clinical, and laboratory data, including PCT and CRP levels and NLR on the day of the BSI, were recorded. Results: A total of 63 patients were included in the analysis, of whom 32 had bacteremia and 31 had candidemia. PCT, CRP, and NLR values were all significantly lower in candidemia compared with bacteremia (0.29 (0.14–0.69) vs. 1.73 (0.5–6.9) ng/mL, p < 0.001, 6.3 (2.4–11.8) vs. 19 (10.7–24.8) mg/dl, p < 0.001 and 6 (3.7–8.6) vs. 9.8 (5.3–16.3), p = 0.001, respectively). PCT was an independent risk factor for candidemia diagnosis (OR 0.153, 95%CI: 0.04–0.58, p = 0.006). A multivariable model consisting of the above three variables had better predictive ability (AUC-ROC = 0.88, p < 0.001), for candidemia diagnosis, as compared to that of PCT, CRP, and NLR, whose AUC-ROCs were all lower (0.81, p < 0.001, 0.78, p < 0.001, and 0.68, p = 0.015, respectively). Conclusions: A combination of routinely available laboratory tests, such as PCT, CRP, and NLR, could prove useful for the early identification of ICU patients with candidemia.

1. Introduction

Intensive care unit (ICU)-acquired bloodstream infections (BSIs) frequently complicate the course of critically ill patients and they are associated with increased morbidity and mortality [1,2]. In addition to bacterial pathogens, fungi, predominantly the Candida species, cause a notable proportion of BSIs with their prevalence increasing worldwide [3,4,5,6].
Early and empirical initiation of appropriate treatment in patients with suspected BSIs is strongly recommended [7], due to its association with a better prognosis [7,8,9,10]. However, early distinction (i.e., prior to the identification of blood pathogens by the microbiology laboratory) of the bacterial or fungal type of a BSI is not feasible, since both types of infection share similar clinical features. Nonetheless, early suspicion, guided by laboratory parameters, could be of great importance in distinguishing the types of BSIs, and thereby offering more individualized treatment. Several laboratory biomarkers indicative of infection, including white blood cells (WBCs) [11] and WBC differential counts [12,13], C-reactive protein (CRP) [14], and procalcitonin (PCT) [15,16], are routinely available in clinical practice and could serve as adjunctive tools in this context.
Particularly, PCT, a prohormone that is the precursor of calcitonin, is a widely used marker that accurately differentiates systemic bacterial infections from noninfectious inflammatory states in ICU patients [14,15,16]. However, in the context of BSIs, the PCT response to Candida species has been less investigated than that to bacterial pathogens. Several studies have suggested a potential role of PCT in discriminating between bacteremia and candidemia in both hospital wards [17,18,19] and the ICU [20,21,22,23,24,25]. High PCT values were predominately associated with bacteremia mainly caused by Gram-negative pathogens, while low PCT values successfully ruled out BSI as a cause of sepsis [26]. Similarly, the highest PCT levels were observed in Gram-negative bacteremia with only marginal increases in fungal infection elsewhere [27]. However, contrasting data have been reported, indicating increased levels of PCT in ICU patients with candidemia [28].
Although a recent systematic review [29] confirmed that serum PCT concentrations were higher in patients with bacteremia compared to those with candidemia, it was recommended that PCT should not be used as a standalone tool for the differential diagnosis between candidemia and bacteremia, due to insufficient supporting evidence. Most of the aforementioned studies have focused exclusively on PCT as a sole biomarker.
Apart from PCT, the information concerning other individual markers of infection as discrimination tools between candidemia and bacteremia is, thus far, scarce. Therefore, there is limited evidence regarding the effectiveness of PCT in combination with biomarkers, such as CRP [22,23,25], WBC count [23,26], or WBC differential, in distinguishing between bacterial and fungal type of BSIs.
The objective of this study was to investigate the usefulness of serum PCT, CRP, neutrophil to lymphocyte count ratio (NLR), as well as their combination, in distinguishing bacterial versus Candida species etiology of BSIs in ICU patients.

2. Methods

2.1. Data Collection

This is a retrospective clinical study, conducted in the ICU of the Evangelismos Hospital, a 1000-bed teaching hospital in Athens, Greece. We searched the hospital electronic record system from April 2012 to October 2014 to identify patients admitted to the ICU who developed BSIs and, additionally, had concomitant measurements of PCT, CRP, and WBC count on the day of blood culture collection. In our ICU, CRP and WBC count measurements were performed as part of daily routine care, whereas PCT assessment was performed only if it was ordered by the attending physician in patients with clinically suspected sepsis. Patients with neutropenia, hematological malignancy, or other hematological disease were excluded. Demographics, date of ICU admission, date of BSI, detected pathogen, admission diagnosis classified as medical or surgical, illness severity, length of stay in ICU, and ICU clinical outcome were recorded. The severity of acute illness was evaluated by the Acute Physiology and Chronic Health Evaluation (APACHE) II score [30] on ICU admission. The severity of organ dysfunction was assessed by the Sequential Organ Failure Assessment (SOFA) score [31], calculated on the first day of ICU admission and, additionally, on the day of BSI. The characteristics of ICU patients who developed bacteremia were compared with those who developed candidemia during their ICU stay. The approval for the use of the de-identified data was obtained from the Ethics Committee of the hospital (protocol number 241/2024). An informed consent from the patient’s next-of-kin was waived.

2.2. Laboratory Methods

CRP was measured by an immunoturbidimetric assay for the in vitro quantitative determination of CRP in human serum on Roche/Hitachi cobas c systems, Roche Diagnostics (Hellas) S.A., Athens, Greece (measuring range 0.30–40.0 mg/dl, normal values < 0.5 mg/dl). PCT was measured by the Elecsys® BRAHMS PCT assay (ElectroChemiLuminescence), Roche Diagnostics (Hellas) S.A., Atens, Greece (limit of detection 0.02 ng/mL, measuring ranges 0.02–100 ng/mL). NLR was calculated by dividing the absolute neutrophil count with the absolute lymphocyte count.

2.3. Microbiological Methods

The BD Bactec (Becton Dickinson, Sparks, MD, USA) automated blood culture system was used for monitoring blood culture bottles. Bacterial and fungal isolates were identified at species level using the VitekMS (BioMeriéux, Marcy l’Étoile, France) device and the MALDI-TOF MS method.

2.4. Definitions

ICU-acquired BSI was defined as that occurring in an ICU patient when one or more cultures of blood, obtained more than 48 h after admission to the ICU, yielded a pathogenic microorganism. Blood culture specimens were ordered by the attending physicians in the presence of clinical features compatible with sepsis or septic shock [11], or when infection was suspected on clinical rounds. The onset of BSI was defined as the date of the blood sampling.
Bacteremia was defined as the recovery of any bacterial species, whereas candidemia was defined as the presence of any Candida species in the blood specimen. When both Candida and bacteria strains were simultaneously grown by the same blood culture, the BSI was not included in the analysis.

2.5. Statistical Analysis

Quantitative data are reported as median and interquartile range (IQR). Qualitative data are reported as number (%). Non-parametric statistical tests were applied, due to the non-normal distribution of the data, as determined by the Kolmogorov–Smirnov test. Comparisons between patients who developed bacteremia vs. candidemia in the ICU were performed using the Mann–Whitney U test. Differences between these two groups of patients in qualitative variables were assessed by Chi-square or Fisher’s exact test when appropriate. Logistic regression analysis was used to build a multivariable model and adjust for confounders. All variables (PCT, CRP, NLR) were log-transformed before entering the model. Receiver operating characteristics–areas under the curve (ROC-AUCs) were used to estimate the predictive performance of various parameters for candidemia diagnosis. Predicted probabilities of the multivariable model, as estimated by the logistic regression, were used to calculate the ROCs-AUCs of the model. Cut-off values for NLR, PCT, CRP, and the model’s predicted probabilities were estimated by Youden’s index. Diagnostic characteristics, such as sensitivity, specificity, positive and negative predictive value (PPV and NPV), and positive and negative likelihood ratio (LR+ and LR−), for the above cut-off values were evaluated. The SPSS statistical program (version 24, Chicago, IL, USA) was used for data analysis. Statistical significance was defined as a two-tailed p value of <0.05.

3. Results

3.1. Patient Characteristics

A total of 63 patients were included in the analysis, of whom 32 (51%) had bacteremia and 31 (49%) had candidemia. The median (IQR) age was 60 (41–74) years, 66% were males, and the crude ICU mortality was 35%. Admission APACHE II and SOFA scores were 20 (15–23) and 10 (5–11), respectively (Table 1). Klebsiella pneumoniae (18%) and Acinetobacter baumannii (8%) were the most frequent bacteria, whereas Candida parapsilosis (21%) and Candida albicans (13%) were the most frequent Candida species (Table 2). NLR, PCT, and CRP were all significantly lower in candidemia compared with bacteremia (6 (3.7–8.6) vs. 9.8 (5.3–16.3), p = 0.001, 0.29 (0.14–0.69) vs. 1.73 (0.5–6.9) ng/mL, p < 0.001, and 6.3 (2.4–11.8) vs. 19 (10.7–24.8) mg/dl, p < 0.001, respectively), see Table 1 and Figure 1.

3.2. Multivariable Logistic Regression Model

We performed a multivariable logistic regression analysis, which revealed PCT as an independent risk factor for candidemia diagnosis (OR: 0.153, 95%CI: 0.04–0.58, p = 0.006), Table 3. Specifically, the higher its levels, the lower the odds of candidemia.

3.3. Diagnostic Characteristics of PCT, CRP, and NLR for Candida BSI

ROC curves were constructed for PCT, CRP, NLR, and the multivariable model, Figure 2 Cut-off values for NLR, PCT, CRP, and the model’s predicted probabilities were estimated by Youden’s index. Then, we calculated all diagnostic characteristics for candidemia prediction for each variable. PCT and CRP had low sensitivity, NPV and LR− (PCT: 0.58, 0.69 and 0.46, CRP: 0.71, 0.75 and 0.34, respectively), but high specificity, PPV and LR+ (PCT: 0.91, 0.86, and 6.18, CRP: 0.84, 0.81, and 4.55, respectively) for candidemia diagnosis. The multivariable model mentioned above (built by the combination of NLR, PCT, and CRP), had a better overall diagnostic performance, showing higher sensitivity and NPV (0.93 and 0.92, respectively), as well as high specificity, PPV, and LR+ (0.77, 0.79, and 4.11, respectively). Furthermore, it had better predictive ability (AUC-ROCs = 0.88, p < 0.001) for candidemia diagnosis, as compared to that of PCT, CRP, and NLR, whose AUC-ROCs were all lower (0.81, p < 0.001, 0.78, p < 0.001, and 0.68, p = 0.015, respectively), Table 4, Figure 2.

4. Discussion

We conducted a retrospective study in septic ICU patients with BSIs seeking to determine routine laboratory tests which could early differentiate candidemia from bacteremia. The main findings of the present study could be summarized as follows: firstly, PCT, CRP, and NLR values were all significantly lower in candidemia compared with bacteremia. Secondly, PCT was an independent risk factor for candidemia diagnosis, after adjustment for the two other biomarkers, CRP and NLR. Third, PCT and CRP had high specificity, PPV, and LR+, but low sensitivity, NPV, and LR−, for candidemia diagnosis. Lastly, the combination of all three parameters had even better diagnostic characteristics, as well as overall predictive performance for candidemia diagnosis (as estimated by ROC-AUCs), compared to each parameter individually.
A recent systematic review [29] summarized the current evidence about PCT values for differentiating candidemia from bacteremia including 16 studies with a total of 45,079 patients and 785 cases of candidemia. Of these studies, 10 exclusively referred to ICU patients. However, the studies identified were clinically very heterogeneous and involved different assessment methods. Although the majority of these studies showed lower PCT values in patients with candidemia compared to bacteremia, the evidence supporting this observation was of low quality and the differences seemed insufficiently discriminative to guide therapeutic decisions. What the present study adds to the field is that the combination of PCT, CRP, and NLR had superior diagnostic characteristics, as well as overall predictive performance, compared to each one of them separately, for the early diagnosis of candidemia, Table 4.
Only a few studies addressed the role of PCT in combination with other biomarkers in discriminating between bacterial and Candida BSIs [22,24,25,26,32]. In accordance with our findings, Fu et al. [22], found that the combination of PCT (cut-off 8.06 ng/mL), CRP (cut-off value 11.6 mg/dl), and IL-6 (cut-off 186.5 pg/mL) increased the sensitivity and specificity for early diagnosis of candidemia and its distinction from Gram-positive/negative bacteremia (AUC = 0.912). In contrast, Martini et al. [24], in a cohort of surgical ICU patients, found that the combination of CRP (with a cut-off value of 10 mg/dl) and PCT (with a cut-off of 2 ng/mL) did not increase sensitivity or specificity for a diagnosis of Candida sepsis. Another study [32] reported improved diagnostic performance for the combination of PCT with (1,3)-β-D-glucan for candidemia.
Due to our local ICU ecology, as previously reported [33], Gram-negative pathogens predominated in the microbiology pattern of BSIs (Table 2). Therefore, in the absence of BSIs caused by Gram-positive pathogens, comparisons were made between candidemia and Gram-negative bacteremia. It should be noted that low levels of PCT in the presence of Gram-positive BSIs have been demonstrated elsewhere [21].
Both bacterial and fungal infections usually cause an increase in the counts of neutrophils, and hence an increase in NLR. NLR is considered a reliable marker for the diagnosis of bacteremia and sepsis and has a potential value in assessing the severity of sepsis [34]. However, to our knowledge, there is a paucity of studies which assess the usefulness of NLR in distinguishing the bacterial or the Candida species etiology of BSIs in ICU patients. We found that NLR was significantly lower in candidemia compared to bacteremia patients. A cut-off value of 12.67 had high sensitivity (0.92), NPV (0.86) and LR+ (1.60), but low specificity (0.41), PPV (0.59) and LR− (0.17). In line with our results, Marik et al. [26] found that the candidemia group had lower NLR compared to that of other pathogens or control groups.
One of the main findings of this study is that in ICU patients with sepsis or septic shock, serum PCT is not markedly elevated at the onset of candidemia, whereas high values are mainly found in bacteremia cases. Similar findings have been reported by several studies so far [20,21,22,23,24,25,27,29,32]. Interestingly, we also found that this occurred independently of the level of systemic inflammation as assessed by CRP levels, as well as of other possible confounding variables, such as NLR. Additionally, a low cut-off value of 0.34 ng/mL had low sensitivity, NPV, and LR− but high specificity, PPV, and LR+ for candidemia diagnosis (Table 4).
To interpret the difference in PCT values between candidemia and bacteremia cases, we must take into account several factors. First, the PCT expression is, at least in part, induced by pro-inflammatory cytokines [35]. The differences in the pathogen-specific signaling could explain the observed differences in the present as well as in other relevant studies. In this context, fungal infection may trigger a different pattern and/or magnitude of cytokine response compared to that encountered during bacterial infections [23,35]. Secondly, a time-related different impairment of the host immune response in the patients with candidemia compared with those with bacteremia may be responsible [23]. Indeed, candidemia occurred significantly later during the ICU stay than did bacteremia in our population (24 vs. 14 days from ICU admission to BSI onset, respectively), which is consistent with the assumption of immune paralysis-related candidemia, due to antecedent septic episodes or any other condition that could inflict upon systemic inflammation.
CRP is a well-known sepsis biomarker [14]. In the present study, it was found to have similar performance to PCT with respect to candidemia diagnosis. Specifically, it was significantly lower in candidemia compared with bacteremia. However, it was not found to be an independent risk factor for candidemia diagnosis. A low cut-off value of 9.75 mg/dl had moderate sensitivity, NPV, and LR−, but a high specificity, PPV, and LR+ for candidemia diagnosis (Table 4). There is limited and conflicting evidence regarding the diagnostic accuracy of CRP in the setting of candidemia in the ICU [22,36,37]. Since PCT may be considered as an acute phase protein like CRP [38], the explanations provided above for the PCT could also apply to CRP.
Certain limitations of the present study should be pointed out. First, since not all consecutive BSIs have been included in the analysis but only those with concomitant PCT measurement, there could be a possibility for selection bias. Second, mixed etiology of BSIs, i.e., bacteremia with concomitant candidemia, were not included. Third, PCT values in cases of negative blood cultures are not available, since only microbiologically documented BSIs have been included. For this reason, a low PCT value should be used cautiously as a single biomarker for early diagnosis of candidemia, since, as expected, negative blood cultures are also associated with low PCT levels [27]. In addition, due to the retrospective type of this single-center study and because of the small number of the included patients, our results cannot be extrapolated. However, this study clearly demonstrates that the combination of easily accessible, everyday clinical laboratory markers had a good diagnostic performance for Candida species BSIs, which could be important for resource-limited regions.
Finally, considering the results of the present study along with those previously reported, it should be noted that, despite the complexity and the limitations of PCT, ICU clinicians, apart from the significance of increased PCT values, should also take into account the low PCT values in the presence of sepsis or septic shock.
In conclusion, PCT was found to be independently associated with candidemia diagnosis in septic ICU patients with BSIs. Specifically, the higher its levels, the lower the odds of candidemia. In addition, its combination with the routinely available biomarkers, CRP and NLR, was superior to early identification of those patients with candidemia. Further studies are required to delineate whether these results might impact current therapeutic algorithms, concerning those patients who would benefit from early appropriate treatment.

Author Contributions

Conceptualization, S.K., E.A. and C.R.; Methodology, S.K. and I.V.; Data curation, A.G., F.C., T.N., G.D., E.T. and P.K.; Formal analysis, S.K. and E.A.; Writing—original draft, S.K., A.G. and C.R.; Writing—review and editing, S.K., E.A., I.V. and C.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was approved by the Ethical committee of Evangelismos Hospital, Athens, Greece (protocol number 241/2024). The need of informed consent was waived because of the retrospective, observational nature of the study.

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets used/or analyzed in the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

APACHEAcute Physiology and Chronic Health Evaluation
BSIBloodstream infection
CIConfidence interval
CRPC-reactive protein
ICUIntensive care unit
IQRInterquartile range
LOSLength of stay
LR−Negative likelihood ratio
LR+Positive likelihood ratio
NLRNeutrophil to lymphocyte count ratio
NPVNegative predictive value
OROdds ratio
PCTProcalcitonin
PPVPositive predictive value
ROC-AUCReceiver operating characteristic-area under the curve
WBCWhite blood cells

References

  1. Timsit, J.-F.; Ruppé, E.; Barbier, F.; Tabah, A.; Bassetti, M. Bloodstream infections in critically ill patients: An expert statement. Intensive Care Med. 2020, 46, 266–284. [Google Scholar] [CrossRef] [PubMed]
  2. Adrie, C.; Garrouste-Orgeas, M.; Essaied, W.I.; Schwebel, C.; Darmon, M.; Mourvillier, B.; Ruckly, S.; Dumenil, A.-S.; Kallel, H.; Argaud, L.; et al. Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy. J. Infect. 2017, 74, 131–141. [Google Scholar] [CrossRef] [PubMed]
  3. Delaloye, J.; Calandra, T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 2014, 5, 161–169. [Google Scholar] [CrossRef] [PubMed]
  4. Routsi, C.; Meletiadis, J.; Charitidou, E.; Gkoufa, A.; Kokkoris, S.; Karageorgiou, S. Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. Antibiotics 2022, 11, 771. [Google Scholar] [CrossRef] [PubMed]
  5. Lortholary, O.; Renaudat, C.; Sitbon, K.; Madec, Y.; Denoeud-Ndam, L.; Wolff, M. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med. 2014, 40, 1303–1312. [Google Scholar] [CrossRef] [PubMed]
  6. Goemaere, B.; Becker, P.; Van Wijngaerden, E.; Maertens, J.; Spriet, I.; Hendrickx, M. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses 2018, 61, 127–133. [Google Scholar] [CrossRef] [PubMed]
  7. Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021, 47, 1181–1247. [Google Scholar] [CrossRef] [PubMed]
  8. Ibrahim, E.H.; Sherman, G.; Ward, S.; Fraser, V.J.; Kollef, M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118, 146–155. [Google Scholar] [CrossRef] [PubMed]
  9. Zaragoza, R.; Artero, A.; Camarena, J.J.; Sancho, S.; González, R.; Nogueira, J.M. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin. Microbiol. Infect. 2003, 9, 412–418. [Google Scholar] [CrossRef] [PubMed]
  10. Morrell, M.; Fraser, V.J.; Kollef, M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 2005, 49, 3640–3645. [Google Scholar] [CrossRef]
  11. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed]
  12. Terradas, R.; Grau, S.; Blanch, J.; Riu, M.; Saballs, P.; Castells, X. Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: A retrospective cohort study. PLoS ONE 2012, 7, e42860. [Google Scholar] [CrossRef] [PubMed]
  13. Liu, X.; Shen, Y.; Wang, H.; Ge, Q.; Fei, A.; Pan, S. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study. Mediat. Inflamm. 2016, 2016, 8191254. [Google Scholar] [CrossRef] [PubMed]
  14. Tan, M.; Lu, Y.; Jiang, H.; Zhang, L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J. Cell Biochem. 2019, 120, 5852–5859. [Google Scholar] [CrossRef] [PubMed]
  15. Assicot, M.; Gendrel, D.; Carsin, H.; Raymond, J.; Guilbaud, J.; Bohuon, C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341, 515–518. [Google Scholar] [CrossRef] [PubMed]
  16. Reinhart, K.; Karzai, W.; Meisner, M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med. 2000, 26, 1193–1200. [Google Scholar] [CrossRef] [PubMed]
  17. Petrikkos, G.L.; Christofilopoulou, S.A.; Tentolouris, N.K.; Charvalos, E.A.; Kosmidis, C.J.; Daikos, G.L. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24, 272–275. [Google Scholar] [CrossRef] [PubMed]
  18. Pieralli, F.; Corbo, L.; Torrigiani, A.; Mannini, D.; Antonielli, E.; Mancini, A. Usefulness of procalcitonin in differentiating Candida and bacterial blood stream infections in critically ill septic patients outside the intensive care unit. Intern. Emerg. Med. 2017, 12, 629–635. [Google Scholar] [CrossRef] [PubMed]
  19. Murri, R.; Mastrorosa, I.; Taccari, F.; Baroni, S.; Giovannenze, F.; Palazzolo, C. Procalcitonin is useful in driving the choice of early antibiotic treatment in patients with bloodstream infections. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 3130–3137. [Google Scholar]
  20. Cortegiani, A.; Russotto, V.; Montalto, F.; Foresta, G.; Accurso, G.; Palmeri, C.; Raineri, S.M.; Giarratano, A. Procalcitonin as a marker of candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol. 2014, 14, 9. [Google Scholar] [CrossRef]
  21. Thomas-Rüddel, D.O.; Poidinger, B.; Kott, M.; Weiss, M.; Reinhart, K.; Bloos, F. MEDUSA study group. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. Crit. Care 2018, 22, 128. [Google Scholar] [CrossRef] [PubMed]
  22. Fu, Y.; Chen, J.; Cai, B.; Zhang, J.; Li, L.; Liu, C.; Kang, Y.; Wang, L. The use of PCT, CRP, IL-6 and SAA in critically ill patients for an early distinction between candidemia and Gram positive/negative bacteremia. J. Infect. 2012, 64, 438–440. [Google Scholar] [CrossRef] [PubMed]
  23. Charles, P.E.; Ladoire, S.; Aho, S.; Quenot, J.P.; Doise, J.M.; Prin, S. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med. 2006, 32, 1577–1583A. [Google Scholar] [CrossRef] [PubMed]
  24. Martini, A.; Gottin, L.; Menestrina, N.; Schweiger, V.; Simion, D.; Vincent, J.L. Procalcitonin levels in surgical patients at risk of candidemia. J. Infect. 2010, 60, 425–430. [Google Scholar] [CrossRef] [PubMed]
  25. Bassetti, M.; Russo, A.; Righi, E.; Dolso, E.; Merelli, M.; Cannarsa, N. Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients. Crit. Care. 2018, 22, 252. [Google Scholar] [CrossRef] [PubMed]
  26. Marik, P.E.; Stephenson, E. The ability of Procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. J. Crit. Care 2020, 60, 135–139. [Google Scholar] [CrossRef] [PubMed]
  27. Oussalah, A.; Ferrand, J.; Filhine-Tresarrieu, P.; Aissa, N.; Aimone-Gastin, I.; Namour, F. Diagnostic accuracy of procalcitonin for predicting blood culture results in patients with suspected bloodstream infection: An observational study of 35,343 consecutive patients (A STROBE-Compliant Article). Medicine 2015, 94, e1774. [Google Scholar] [CrossRef] [PubMed]
  28. Yazdani, M.R.; Khorvash, F.; Hakamifard, A. Serum Procalcitonin Levels of Patients with Candidemia Hospitalized in Intensive Care Units. J. Med. Sci. 2018, 38, 113–116. [Google Scholar]
  29. Cortegiani, A.; Misseri, G.; Ippolito, M.; Bassetti, M.; Giarratano, A.; Martin-Loeches, I. Procalcitonin levels in candidemia versus bacteremia: A systematic review. Crit. Care 2019, 23, 190. [Google Scholar] [CrossRef]
  30. Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. APACHE II: A severity of disease classification system. Crit. Care Med. 1985, 13, 818–829. [Google Scholar] [CrossRef]
  31. Vincent, J.L.; de Mendonça, A.; Cantraine, F.; Moreno, R.; Takala, J.; Suter, P.M. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Crit. Care Med. 1998, 26, 1793–1800. [Google Scholar] [CrossRef] [PubMed]
  32. Giacobbe, D.R.; Mikulska, M.; Tumbarello, M.; Furfaro, E.; Spadaro, M.; Losito, A.R.; Mesini, A.; De Pascale, G.; Marchese, A.; Bruzzone, M.; et al. Combined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Crit. Care 2017, 21, 176. [Google Scholar] [CrossRef] [PubMed]
  33. Routsi, C.; Gkoufa, A.; Arvaniti, K.; Kokkoris, S.; Tourtoglou, A.; Theodorou, V.; Vemvetsou, A.; Kassianidis, G.; Amerikanou, A.; Paramythiotou, E.; et al. De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: A multicentre prospective observational cohort study in patients with sepsis or septic shock. J. Antimicrob. Chemother. 2020, 75, 3665–3674. [Google Scholar] [CrossRef] [PubMed]
  34. Drăgoescu, A.N.; Pădureanu, V.; Stănculescu, A.D.; Chiuțu, L.C.; Tomescu, P.; Geormăneanu, C.; Pădureanu, R.; Iovănescu, V.F.; Ungureanu, B.S.; Pănuș, A.; et al. Neutrophil to Lymphocyte Ratio (NLR)-A Useful Tool for the Prognosis of Sepsis in the ICU. Biomedicines 2021, 10, 75. [Google Scholar] [CrossRef] [PubMed]
  35. Matwiyoff, G.N.; Prahl, J.D.; Miller, R.J.; Carmichael, J.J.; Amundson, D.E.; Seda, G.; Daheshia, M. Immune regulation of procalcitonin: A biomarker and mediator of infection. Inflamm. Res. 2012, 61, 401–409. [Google Scholar] [CrossRef] [PubMed]
  36. Wang, Q.; Wang, C.; Yang, M.; Li, X.; Cui, J.; Wang, C. Diagnostic efficacy of serum cytokines and chemokines in patients with candidemia and bacteremia. Cytokine 2020, 130, 155081. [Google Scholar] [CrossRef] [PubMed]
  37. Akin, H.; Akalin, H.; Budak, F.; Ener, B.; Ocakoğlu, G.; Gürcüoğlu, E.; Göral, G.; Oral, H.B. Alterations of serum cytokine levels and their relation with inflammatory markers in candidemia. Med. Mycol. 2015, 53, 258–268. [Google Scholar] [CrossRef]
  38. Nijsten, M.W.N.; Olinga, P.; de Vries, E.G.E.; Schraffordt Koops, H.; Groothuis, G.M.M.; Limburg, P.C.; ten Duis, H.J.; Moshage, H.; Hoekstra, H.J.; Bijzet, J.; et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit. Care Med. 2000, 28, 458–461. [Google Scholar] [CrossRef]
Figure 1. Boxplots of (A) PCT, (B) CRP, and (C) NLR, in patients with bacteremia and candidemia.* p < 0.001, # p = 0.015. Abbreviations: PCT, procalcitonin; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.
Figure 1. Boxplots of (A) PCT, (B) CRP, and (C) NLR, in patients with bacteremia and candidemia.* p < 0.001, # p = 0.015. Abbreviations: PCT, procalcitonin; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.
Jcm 13 03557 g001
Figure 2. ROC curves for candidemia diagnosis of (A) PCT, (B) CRP, (C) NLR, and (D) a multivariable model consisted of the combination of all three markers. Abbreviations: ROC, receiver operating characteristic; PCT, procalcitonin; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.
Figure 2. ROC curves for candidemia diagnosis of (A) PCT, (B) CRP, (C) NLR, and (D) a multivariable model consisted of the combination of all three markers. Abbreviations: ROC, receiver operating characteristic; PCT, procalcitonin; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.
Jcm 13 03557 g002
Table 1. Patient baseline characteristics and laboratory tests on day of BSI occurrence.
Table 1. Patient baseline characteristics and laboratory tests on day of BSI occurrence.
All Patients
(n = 63)
Bacteremia
(n = 32)
Candidemia
(n = 31)
p-
Value
Age, years60(41–74)60(44–66)63(39–75)0.62
Sex (male), n (%)41(66)21(68)20(64)0.78
Admission category 0.26
Surgical, n (%)28(44)12(37)16(52)
Medical, n (%)35(56)20(62)15(48)
Outcomes
ICU mortality, n (%)22(35)14(44)8(26)0.32
ICU-LOS, days42(26–58)43(24–57)35(26–82)0.77
Severity scores
SOFA on admission10(5–11)9(5–11)10(6–12)0.66
APACHE II on admission20(15–23)20(15–24)19(15–22)0.59
SOFA on BSI day8(5–11)10(6–12)6(4–10)0.08
BSI day since admission, days24(10–42)14(5–29)24(15–42)0.16
Laboratory tests on BSI day
WBCs, ×109/l11.79(8.47–18.38)17.09(10.86–22.83)8.93(6.77–12.82)<0.001
Lymphocytes, ×109/l1.41(0.94–1.84)1.47(1.01–1.94)1.38(0.88–1.77)0.42
PMN, ×109/l8.56(5.96–15.57)13.0898.10–19.13)6.30(5.71–10.05)0.001
NLR7.06(4.56–13.34)9.79(5.29–16.26)6.04(3.71–8.58)0.015
CRP, mg/dl10.7(4.3–20.9)19.0(10.7–24.7)6.3(2.4–11.8)<0.001
PCT, ng/mL0.62(0.24–2.85)1.73(0.51–6.91)0.29(0.14–0.69)<0.001
Data are expressed as median (IQR), unless otherwise defined. Abbreviations: BSI, blood stream infection; ICU, intensive care unit; LOS, length of stay; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; WBCs, white blood cells; PMN, polymorphonuclears; NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; PCT, procalcitonin; IQR, interquartile range.
Table 2. Candidemia and bacteremia species.
Table 2. Candidemia and bacteremia species.
n%
Candidemia species
Candida parapsilosis1320.6
Candida albicans812.7
Candida glabrata34.8
Candida tropicalis11.6
Candida luzitanea11.6
Candida crusei11.6
Bacteremia species
Klebsiella pneumoniae1117.5
Acinetobacter baumanni57.9
Pseudomonas aeruginosa57.9
Providencia stuartii57.9
Other bacteria/fungi914
Table 3. Multivariable logistic regression model for candidemia diagnosis.
Table 3. Multivariable logistic regression model for candidemia diagnosis.
VariableB Coefficientp-ValueOR95%CI
Log[PCT] −1.8790.0060.1530.040–0.580
Log[CRP]−1.1900.2050.3040.048–1.914
LogNLR−1.8810.0970.1520.016–1.408
Brackets denote concentration. Abbreviations: OR, odds ratio; CI, confidence interval; PCT, procalcitonin; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.
Table 4. Diagnostic tests of PCT, CRP, NLR, and their combination, for candidemia.
Table 4. Diagnostic tests of PCT, CRP, NLR, and their combination, for candidemia.
Cut-Off Value *PCT = 0.34 ng/mLCRP = 9.75 mg/dlNLR = 12.67Model’s Predicted Probability = 0.40
Sensitivity0.58 [0.41–0.73]0.71 [0.53–0.84]0.92 [0.77–0.98]0.93 [0.77–0.98]
Specificity0.91 [0.76–0.97]0.84 [0.68–0.93]0.41 [0.26–0.59]0.77 [0.60–0.88]
PPV0.86 [0.65–0.95]0.81 [0.63–0.92]0.59 [0.44–0.72]0.79 [0.62–0.89]
NPV0.69 [0.54–0.81]0.75 [0.59–0.86]0.86 [0.62–0.96]0.92 [0.76–0.98]
LR+6.18 [2.02–18.94]4.55 [1.97–10.48]1.60 [1.16–2.19]4.11 [2.12–7.95]
LR−0.46 [0.30–0.71]0.34 [0.19–0.61]0.17 [0.04–0.69]0.09 [0.02–0.35]
ROC-AUC0.81 [0.71–0.92] #0.78 [0.67–0.90] #0.68 [0.55–0.82] $0.88 [0.78–0.97 ] #
Data within brackets indicate 95% confidence interval. *, Cut-off values for NLR, PCT, CRP, and the model’s predicted probabilities were estimated by Youden’s index. The model consisted of the combination of PCT, CRP, and NLR. #, p < 0.001, $, p = 0.015. Abbreviations: PCT, procalcitonin; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio; ROC-AUC, receiver operating characteristics–area under the curve.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kokkoris, S.; Angelopoulos, E.; Gkoufa, A.; Christodouli, F.; Ntaidou, T.; Theodorou, E.; Dimopoulou, G.; Vasileiadis, I.; Kremmydas, P.; Routsi, C. The Diagnostic Accuracy of Procalcitonin and Its Combination with Other Biomarkers for Candidemia in Critically Ill Patients. J. Clin. Med. 2024, 13, 3557. https://doi.org/10.3390/jcm13123557

AMA Style

Kokkoris S, Angelopoulos E, Gkoufa A, Christodouli F, Ntaidou T, Theodorou E, Dimopoulou G, Vasileiadis I, Kremmydas P, Routsi C. The Diagnostic Accuracy of Procalcitonin and Its Combination with Other Biomarkers for Candidemia in Critically Ill Patients. Journal of Clinical Medicine. 2024; 13(12):3557. https://doi.org/10.3390/jcm13123557

Chicago/Turabian Style

Kokkoris, Stelios, Epameinondas Angelopoulos, Aikaterini Gkoufa, Foteini Christodouli, Theodora Ntaidou, Evangelia Theodorou, Georgia Dimopoulou, Ioannis Vasileiadis, Panagiotis Kremmydas, and Christina Routsi. 2024. "The Diagnostic Accuracy of Procalcitonin and Its Combination with Other Biomarkers for Candidemia in Critically Ill Patients" Journal of Clinical Medicine 13, no. 12: 3557. https://doi.org/10.3390/jcm13123557

APA Style

Kokkoris, S., Angelopoulos, E., Gkoufa, A., Christodouli, F., Ntaidou, T., Theodorou, E., Dimopoulou, G., Vasileiadis, I., Kremmydas, P., & Routsi, C. (2024). The Diagnostic Accuracy of Procalcitonin and Its Combination with Other Biomarkers for Candidemia in Critically Ill Patients. Journal of Clinical Medicine, 13(12), 3557. https://doi.org/10.3390/jcm13123557

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop